Transcode Therapeutics, Inc.
RNAZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829635
No open-market purchases or sales by Transcode Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $208.1K in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Transcode Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 11 | 5 | −6 |
| Shares | 262.2K | 207.3K | −54.9K (−21.0%) |
| Value | $88.6K | $476.6K | +$388.0K (+437.7%) |
New holders (3)
Institutions that held Transcode Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sabby Management, LLC | 188,437 | $433.4K | 1.55% |
| Susquehanna International Group, LLP | 13,662 | $31.4K | 0.00% |
| Royal Bank of Canada | 45 | $0 | 0.00% |
Sold out (9)
Institutions that held Transcode Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Geode Capital Management, LLC | 75,683 | $25.6K |
| Sheets Smith Wealth Management | 60,000 | $20.3K |
| One68 Global Capital, LLC | 30,120 | $10.2K |
| State Street Corp | 21,019 | $7.12K |
| Warberg Asset Management LLC | 20,000 | $6.77K |
| Two Sigma Investments, LP | 19,407 | $6.57K |
| Shay Capital LLC | 15,060 | $5.10K |
| Goldman Sachs Group Inc | 13,122 | $4.44K |
| BlackRock Inc. | 1,385 | $469 |